Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
PD-1 / PD-L1 antibodies block the programmed cell death protein 1 (PD-1) checkpoint on T cells or its ligand PD-L1. Binding of PD-L1 on tumor or antigen-presenting cells to PD-1 suppresses T-cell activation, so blocking either partner restores effector function in co-culture and tumor models. Anti-PD-1 antibodies in this group include pembrolizumab, nivolumab, cemiplimab, dostarlimab, tislelizumab and toripalimab. Atezolizumab, durvalumab and avelumab bind PD-L1 instead, and avelumab retains antibody-dependent cell-mediated cytotoxicity (ADCC). The antibodies serve as reference reagents in checkpoint blockade assays, receptor occupancy studies and combination experiments.
Synonyms: Anti-Human PD-L1; Human Antibody; MSB 0010718C
Avelumab is a fully human IgG1 monoclonal antibody targeting PD-L1, facilitating antibody-dependent cell-mediated cytotoxicity (ADCC). It has shown the ability to enhance ADCC in various cancer cell lines that express PD-L1. This reagent is primarily applicable in research focused on chordoma and related oncological studies.
Lipustobart is a humanized IgG4κ monoclonal antibody directed against PD-1 (programmed cell death protein 1 / CD279), a key immune checkpoint receptor involved in T cell regulation. By blocking PD-1 signaling, Lipustobart restores T cell activity and promotes antitumor immune responses. This antibody is suitable for research in cancer immunotherapy, immune checkpoint blockade, and T cell exhaustion.
Vudalimab is a fully human bispecific monoclonal antibody targeting both PD-1 and CTLA-4, two key immune checkpoint receptors. By simultaneously blocking these pathways, Vudalimab enhances T-cell activation in the tumor microenvironment and is widely used in research on immune checkpoint blockade, tumor immunology, and combination immunotherapy strategies.
Synonyms: SCT-I10A
Finotonlimab (SCT-I10A) is a recombinant humanized IgG monoclonal antibody targeting PD-1, a critical immune checkpoint molecule. By blocking PD-1 signaling, Finotonlimab restores T cell activity and is applicable in research on solid tumors, lymphomas, and immune checkpoint inhibitor development.
Tislelizumab is a humanized monoclonal antibody that binds to the PD-1 receptor, effectively blocking its interaction with the ligands PD-L1 and PD-L2. By reactivating exhausted T cells, Tislelizumab enhances antitumor immunity. It is widely used in immuno-oncology research, including studies on Hodgkin’s lymphoma, urothelial carcinoma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma.
Synonyms: MK-3475; Lambrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 monoclonal antibody that targets PD-1, a key immune checkpoint receptor. It inhibits the PD-1/PD-L1 pathway, restoring T cell activity and promoting tumor cell clearance. Pembrolizumab is a standard research tool for cancer immunotherapy and immune checkpoint inhibitor studies across a wide range of solid tumors.
Synonyms: HBM-9167; KL-A167
Tagitanlimab (HBM-9167) is a humanized monoclonal antibody of the IgG1κ isotype, designed to selectively inhibit the interaction between programmed death-ligand 1 (PD-L1) and its receptor PD-1. This interaction blockade is pivotal in modulating the immune system's response to tumor cells, potentially enhancing anti-tumor activity. Tagitanlimab is primarily investigated for its therapeutic potential in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), positioning it as a significant candidate for oncology research.
Gilvetmab is a caninized anti-PD-1 monoclonal antibody designed to exhibit potent inhibitory effects on the PD-1/PD-L1 interaction. By blocking this pathway, Gilvetmab effectively disrupts a critical immune checkpoint mechanism, thereby enhancing T-cell function and immune response against tumor cells. This antibody is specifically tailored for use in research related to malignant melanoma, providing a valuable tool for investigating the role of the PD-1/PD-L1 pathway in cancer immunotherapy.
Synonyms: AGEN2034
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody designed to selectively target and inhibit the programmed cell death protein 1 (PD-1). This interaction is intended to enhance the body's immune response against various cancers by blocking the PD-1 pathway, which is often exploited by tumors to evade immune detection.
Synonyms: MSB-2311
Betifisolimab (MSB-2311) is a humanized monoclonal antibody that targets the immunosuppressive ligand PD-L1. This antibody is designed for investigative use in the study of advanced solid tumors and hematological malignancies, offering a promising tool for research into tumor immunology and potential therapeutic interventions.
Synonyms: IBI308
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody designed to selectively bind to the programmed death-1 (PD-1) receptor with a dissociation constant (KD) of 74 pM. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Sintilimab effectively restores the body's endogenous antitumor T-cell response. Research indicates that when combined with prebiotics, Sintilimab effectively reduces tumor volume and modulates the balance of immune cell subpopulations in mouse models of lung adenocarcinoma. This antibody is primarily used in the investigation of classical Hodgkin's lymphoma, non-small cell lung cancer, and esophageal cancer, making it a valuable tool for oncological research and therapeutic explorations.
Synonyms: PSB-205; QL1706 (iparomlimab/tuvonralimab; PBS105
Tuvonralimab (PSB-205; QL1706) is a dual-action immunotherapy agent comprising a combination of Iparomlimab, an anti-PD-1 IgG4 antibody, and Tuvonralimab, an anti-CTLA-4 IgG1 antibody. This formulation is designed to synergistically inhibit both the PD-1 and CTLA-4 immune checkpoints, enhancing antitumor immune responses. Tuvonralimab is utilized primarily in research focused on cancer immunotherapy, aiming to study and potentially enhance the efficacy of checkpoint blockade strategies.
Synonyms: BGB-A333
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody engineered to specifically target and bind to the programmed death-ligand 1 (PD-L1). This antibody selectively inhibits the interaction between PD-L1 and its receptor, programmed death-1 (PD-1), a critical pathway exploited by tumors to evade immune detection. Through this mechanism, Garivulimab exhibits potent antitumor activity, making it a valuable tool for cancer immunotherapy research.
Synonyms: AMG-404
Zeluvalimab (AMG-404) is a monoclonal antibody specifically designed to target the PD-1 receptor. This antibody is utilized primarily in the research of various cancer types, facilitating studies focused on immune checkpoint inhibition and tumor immune evasion mechanisms. Zeluvalimab serves as a critical tool in oncology research, offering potential insights into the modulation of immune responses against tumor cells.
Synonyms: ANB030
Rosnilimab is a humanized IgG1 kappa monoclonal antibody specifically designed to target and bind to the programmed cell death protein 1 (PD-1). This interaction inhibits PD-1 signaling, which can enhance the immune system's ability to fight cancer. Rosnilimab is primarily used in research focused on the modulation of immune checkpoints in oncology.
Synonyms: AZD-2936
Rilvegostomig is a human IgG1 κ monoclonal antibody targeting PDCD1 and TIGIT. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.
Synonyms: PDR001
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody designed to bind to programmed death-1 (PD-1) receptor with subnanomolar affinity. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Spartalizumab effectively modulates immune responses. This antibody is primarily utilized in research focused on anaplastic thyroid carcinoma (ATC), providing a valuable tool for investigating immune checkpoint pathways in cancer immunotherapy studies.
Synonyms: MGD-013
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific antibody designed for dual affinity re-targeting (DART) of PD-1 and LAG-3. This therapeutic agent demonstrates high affinity binding to cell-surface expressed PD-1 and LAG-3, with half-maximal effective concentrations (EC50s) of 1.65 nM and 0.41 nM in NS0 cells, respectively. By effectively blocking the interactions between PD-1/PD-L1, PD-1/PD-L2, and LAG-3/HLA (MHC-II), as well as inhibiting PD-1 signaling pathways, Tebotelimab plays a crucial role in restoring the function of exhausted T-cells. This restoration is pivotal in enhancing anti-tumor immunity, making Tebotelimab a significant tool in cancer immunotherapy research.
Synonyms: LY-3462817
Peresolimab is a humanized IgG1-κ monoclonal antibody designed to specifically target PD-1 (Programmed Death-1). This antibody functions by potentially stimulating physiological immune inhibitory pathways, thereby aiming to restore immune homeostasis. Peresolimab is utilized primarily in research focused on the modulation of immune checkpoint pathways, which are critical for understanding and manipulating immune responses in various disease states, including oncology and autoimmune disorders.
Synonyms: MPDL3280A
Atezolizumab (MPDL3280A) is a humanized monoclonal IgG1 antibody selectively targeting programmed death ligand 1 (PD-L1). This antibody is utilized extensively in oncological research to investigate the modulation of the immune system's response against cancer cells. Atezolizumab's specificity for PD-L1 aids in the study of immune checkpoint pathways, potentially leading to new therapeutic strategies in cancer treatment.
Synonyms: GLS-010; AB-122; WBP-3055
Zimberelimab (GLS-010) is a fully human monoclonal antibody of the IgG4 subclass that targets PD-1 with a high affinity, demonstrated by an EC50 of 210 pM. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, with IC50 values of 580 pM and 670 pM respectively, in CHO-S cell assays. Zimberelimab has been shown to exhibit potent antitumor activities. It is applicable in the research of various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin’s lymphoma, making it a valuable tool for oncological studies focused on immune checkpoint pathways.
Synonyms: CK-301; TG-1501
Cosibelimab (CK-301; TG-1501) is a fully human monoclonal antibody with high affinity for PD-L1, effectively inhibiting its interaction with PD-1. This antibody features a functional Fc domain, enabling it to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms facilitate the targeted killing of PD-L1-expressing cell lines, including various lymphoma cells, making it a critical tool for research in oncology and immunotherapy.
Synonyms: CT-011; MDV9300
Pidilizumab (CT-011) is a humanized IgG1k monoclonal antibody targeting PD-1. It functions as a DLL1 antagonist, offering significant potential for research into hematologic malignancies. This antibody is designed for specificity to PD-1, making it a valuable tool for studies focused on immune checkpoint pathways and their roles in cancer immunotherapy.
Synonyms: MEDI 4736
Durvalumab (MEDI4736) is a human monoclonal antibody targeting PD-L1. This antibody effectively inhibits the interaction of PD-L1 with its receptors PD-1 and CD80, demonstrating inhibitory concentrations (IC50) of 0.1 nM and 0.04 nM, respectively. Durvalumab's high specificity and potent binding affinity make it a valuable tool for research into checkpoint inhibition and immune response modulation.
Synonyms: IMC-001; STI-3031
Danburstotug (IMC-001) is a human monoclonal antibody of the IgG1-lambda isotype, specifically targeting CD274, also known as PDL1 or B7-H1. This antibody functions as both an immunostimulant and an antineoplastic agent, making it applicable in the study of immune checkpoint pathways and cancer immunotherapy.
